Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05933395 · ClinicalTrials.gov registry record · Phase 2
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
A Phase 2 study of Advanced Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT05933395: Recruiting Phase 2 study of Advanced Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center.
NCT05933395 is a Phase 2 study of Advanced Breast Cancer that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 135 participants, below the 460-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05933395, a Phase 2 study of Advanced Breast Cancer, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
Primary Outcome
Clinical benefit rate will be measured as the proportion of participants who experience stable disease (SD) at 24 weeks, complete response, and partial response per RECIST 1.1.
Conditions Studied
Interventions
- DRUG Neratinib
- DRUG Everolimus
- DRUG Fulvestrant
- DRUG Abemaciclib
- DRUG Alpelisib
Study Locations (1)
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2031-10 |
| Phase | Phase 2 |
What NCT05933395 shows while recruiting
NCT05933395 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 460-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Advanced Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Neratinib is the first listed.
NCT05933395 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05933395 about?
NCT05933395 is a clinical study titled "Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor". The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
What is the current status of trial NCT05933395?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2024-09-23. Estimated completion is 2031-10.
What conditions does trial NCT05933395 study?
This clinical trial studies the following conditions: Advanced Breast Cancer.
What interventions are being tested in trial NCT05933395?
The interventions under investigation include: Neratinib (DRUG), Everolimus (DRUG), Fulvestrant (DRUG), Abemaciclib (DRUG), Alpelisib (DRUG).
Who is sponsoring clinical trial NCT05933395?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05933395 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05933395's enrollment target sits among peer trials
135 18th of 28 higher than 11 of 28 other Advanced Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
RECRUITING · Phase 2
-
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
ACTIVE NOT RECRUITING · Phase 2
-
RCT of CBD for Anxiety in Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI